Avandia Medical and Legal News

Heart and Diabetes Groups Urge Caution
The conclusions of this analysis of previous studies of rosiglitazone (brand name, Avandia) suggest that this oral agent used to treat type 2 diabetes may be associated with increased risk of heart attack and death from cardiovascular causes.

China Not Affected By Avandia Diabetes Drug Research
A research report suggesting that a GlaxoSmithKline-manufactured diabetes drug can increase the risk of heart attack has had little effect on the use of the drug in China, a hospital official said. Avandia, known by its generic name as rosiglitazone maleate, has been widely used in the treatment of type 2 diabetes.

Take Measured Approach In Response To Potential Avandia Risks
The Endocrine Society urges physicians to respond in a measured way to a recent study suggesting the diabetes drug Avandia (rosiglitazone) increases the risk of heart disease and heart attacks.

Avandia Linked to Increased Risk of Heart Attack
The Food and Drug Administration (FDA) issued a safety alert on diabetes drug Avandia after studies found a potentially significant increased rate of heart-related deaths among patients taking the diabetes drug.

Warning on Avandia Is Old News In Europe
GSK strongly disagrees with conclusions reached in NEJM article on Avandia, but Europe's main medical regulator reiterated that it had strengthened warnings about Avandia's cardiovascular risks last fall based on company data available to regulators on both sides of the Atlantic.

Major Heart, Diabetes Groups Urge Caution in Wake of Avandia Warning
"The risk of heart attack and death for type 2 diabetes patients taking the drug Avandia appears to be small, but must be considered carefully” says a statement issued by the American College of Cardiology, American Diabetes Association, and American Heart Association. They advise patients using this drug should talk to their health care provider to determine the most appropriate course of action.

Avandia Risks Prompt Doctors to Switch Drugs
Boston doctor Annaswamy Raji says she was so alarmed by a study linking GlaxoSmithKline Plc's drug Avandia to heart disease that she immediately advised a diabetes patient to stop taking the medicine.

FDA Issues Safety Alert on Avandia
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia.

Avandia Search Engine
7141 Oak Pointe Curve
Minneapolis, MN 55438 USA

This domain's value was grown by Domain Incubation

©Copyright
Nielsen Technical Services
All Rights Reserved Worldwide

Other Resources
Phone Cards
Bee Zaagar
Legal Search Engine
International Phone Cards